Linezolid: suitability of prescription and its effects on renal function and haematology

Authors

  • JA MORALES-MOLINA Servicio de Farmacia. Hospital del Mar. Barcelona.
  • S GRAU Servicio de Farmacia. Hospital del Mar. Barcelona.
  • J JIMÉNEZ-MARTÍN Departamento de Farmacología. Facultad de Farmacia. Universidad de Granada
  • J MATEU-DE ANTONIO Servicio de Farmacia. Hospital del Mar. Barcelona.
  • A ZARZUELO Departamento de Farmacología. Facultad de Farmacia. Universidad de Granada
  • E SALAS Servicio de Farmacia. Hospital del Mar. Barcelona.

Keywords:

Linezolid, Thrombocytopenia, Renal function, Indications, Gram positive microorganisms

Abstract

The objective of the study was to evaluate the suitability of linezolid prescription, incidence of thrombocytopenia incritically ill patients and its infl uence on critical ill patients with renal disorder before the linezolid treatment. Weobserved that the 37.5% of linezolid prescriptions were in Non-Approved Indications in Spain (NAIS). The incidenceof thrombocytopenia was 5.9%. We observed a signifi cant improvement in renal function of patients after two weeks oflinezolid treatment (p=0.024). The incidence of thrombocytopenia was similar to describe in bibliography. It seems tobe necessary approved news indications in Spain.

Downloads

Download data is not yet available.

References

Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41(10):2132-2136.

Clemett D, Markham A. Linezolid. Drugs 2000; 59:815-30.

Mensa J, Gatell JM, Azanza JR, Domínguez-Gil A, García JE, Jiménez de Anta MT, et al. Guía de Terapéutica Antimicrobiana

Ed. 15:106.

European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infections Diseases (ESCMID). EUCAST Definitive Document. E. Def. 4.1 Dec. 2000.

Zyvox (linezolid) package insert. Kalamazoo, MI: Pharmacia & Upjohn; 2001.

Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ulanowicz DA, Garmon SA, et al. Syntesis and antibacterial activity of U-100592 and U-100766, 2 oxazolidonone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 1996; 39: 673-9.

Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Invest Drugs 1999; 8:1195-

Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42:3251-3255.

Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U–100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40:839-45.

Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbial Infect Dis 1999; 33:101-12.

Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U–100592 and U-100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996; 40:799-801.

Prystowszky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin resistant enterococci. Antimicrob Agents Chemother 2001; 45:2154-6.

Paladino J. A. Linezolid: una oxazolidinona antimicrobiana. Am J Health System Pharm 2003; 2 (3):151-160.

Xiong L, Kloss P, Douthwaite S, Andersen NM, Swaney S, Shinabarger DL, et al. Oxazolidinone resistance mutations in 23 rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol 2000; 182:5325-31.

Tsiodras S, Gold HS, Sakoulas G, Eliopoulus GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8.

Slatter JG, Stalker DI, Feenstra KL, Welshman IR. Pharmacokinetics, metabolism, and excretion of linezolid following

and oral dose of (14 C) linezolid to healthy human subjects. Drug Metab Dispos. 2001; 29:1136-45.

Kuter DJ, Tillotson GS. Hematological effects of antimicrobials, a focus on the oxazolidinone, linezolid. Pharmacotherapy 2001; 21:1010-3.

Linezolid. Drug Evaluation Monographs. DRUGDEX System. Drug Information. Micromedex Computerized Clinical Information System. Englewood. Colorado 2002; Vol 111. Página localizable en la dirección http://www.sefh.es/micromedex.htm.

Perry CM, Jarvis B. Linezolid: revisión de su uso en el tratamiento de las infecciones graves por grampositivos. Drugs 2001; 61:525-52.

Linezolid USP DI. Drug Information for the Health Care Professional. Micromedex Computerized Clinical Information System. Englewood, Colorado 2002; Vol. 111. At http://www.sefh.es/micromedex.htm.

Physicians Desk Reference, 55th Ed. USA: Medical Economics Company 2001.

Cupo-Abbott J. Linezolid: A synthetic oxazolidinone antimicrobial for treatment of serious Gram-positive infectious. Formulary 2000; 35:483-97.

American Health-System Pharmacists Society. Drug Information ASHP. Bethesda 2001.

Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34:695-8.

Waldrep TW, Skies DJ. Linezolid-Induced anemia and thrombocytopenia. Pharmacotherapy 2002; 22:109-12.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine. A new prediction equation. Ann Intern Med 1999; 130:461-470

Carmona PM, Romá E, Monte E, Garcia J, Gobernado M. Papel de linezolid en terapéutica antimicrobiana. Enferm Infecc Microbiol Clin 2003; 21(1):39.

Green SL, Madox JC, Huttenbach ED. Linezolid and reversible myelosupression. JAMA 2001; 285:1291.

Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O`Grady M, et al. Pharmacokinetics of linezolid in Subjects with Renal Dysfunction. Antimicrob Agents Chemother 2003 september; 2775-80.

Downloads

Published

2006-12-20

How to Cite

1.
MORALES-MOLINA J, GRAU S, JIMÉNEZ-MARTÍN J, MATEU-DE ANTONIO J, ZARZUELO A, SALAS E. Linezolid: suitability of prescription and its effects on renal function and haematology. Ars Pharm [Internet]. 2006 Dec. 20 [cited 2024 Jul. 22];47(4):363-74. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/5038

Issue

Vol. 47 No. 4 (2006)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).